Early Marijuana Use Tied to Adult Psychosis Risk

BY MARY ANN MOON

The use of cannabis at a younger age is associated with psychosis symptoms in early adulthood, according to a study published online in the Archives of General Psychiatry.

Earlier studies had found a link between early-onset cannabis use and later symptoms of psychosis, but those studies had “lingering concerns that the association may reflect methodological biases and unmeasured residual confounding,” in those studies. Dr. McGrath and his associates examined the link using data from a birth cohort of more than 7,000 mother-infant pairs who were first studied in 1981-1984 and followed up 5, 14, and 21 years later.

A total of 3,801 of these infants and their close-in-age siblings comprised the subjects in this study. The latest follow-up occurred when they were aged 18-23 years. At that time, about 18% of the subjects said they had been using marijuana for 3 or fewer years, 16% said they had been using it for 4-5 years; and 14% said they had been using it for 6 or more years.

At this final follow-up, 65 of these subjects had received diagnoses of non-affective psychosis because they met the criteria for schizophrenia (53 subjects), persistent delusional disorder (3), or acute transient psychotic disorders in 21-item PDI and to report hallucinations on the CIDI.

Moreover, the longer the interval since first cannabis use, the higher the risk of these adverse psychosis-related outcomes. In a subsample of 218 sibling pairs, there was a significant association between earlier first use of cannabis and higher scores on the PDI for every additional year since first exposure to marijuana, the sibling with the younger age at first use scored one item higher than the other sibling, wrote the authors.

This study could delineate an association between early marijuana use and later symptoms of psychosis, and was not designed to determine causality. “We cannot confidently exclude the possibility that some of the cohort members may have developed psychosis as young adolescents, which may have contributed to subsequent (early) cannabis use,” they added.

The National Health and Medical Research Council of Australia funded the study.

VITALS

Major Finding: Those who started using marijuana at 15 were twice as likely to receive a diagnosis of nonaffective psychosis in young adulthood as their counterparts who said they never used.


Disclosures: None of the investigators had any financial conflicts of interest to report.

Science and Savings.*

In major depressive disorder

Now, the generic equivalent of PAXIL CR™ is dispensed to 84% of patients.*

Mylan Pharmaceuticals — the company pharmacists rank first in quality — has made a science out of producing affordable medication for almost 50 years. In less than one year, MYLAN PAROXETINE HYDROCHLORIDE Extended-release Tablets have become the #1 most dispensed long-acting paroxetine HCl — more than 1.3 million prescriptions filled so far!

Mylan
PAROXETINE HYDROCHLORIDE
Extended-release tablets


*Data on file: Mylan Pharmaceuticals Inc.
‡Preparations in Prescription Audit: Total Prescriptions.
§Mylan Paroxetine HCl Product: Prescribing Information for Pharmacy Use.
**In accordance with the need for close observation and communication with the prescriber.

Mylan Pharmaceuticals Inc. 800-Rx-MYLAN • www.mylan.com